Advanced Insulin Technology Plus Support Helped a Man With 55 Years of Type 1 Diabetes

When a 66-year-old man visited the Diabetes Clinic at the University Hospital in Krakow, he brought with him 55 years of type 1 diabetes history. Diagnosed in 1969, he had experienced many of the serious complications that can develop over decades: damage to nerves in his feet and body (polyneuropathy and autonomic neuropathy), advanced eye disease from diabetes (retinopathy), and hypoglycemia unawareness—meaning his body no longer reliably warned him when his blood sugar was dropping dangerously low.

Despite his careful self-management over the years, his blood sugar remained difficult to control. His HbA1c (average blood sugar over three months) was 9.2%, well above the typical target range. He experienced significant swings in his glucose levels throughout the day, and the fear of severe low blood sugar episodes had led him to underdose his insulin—a coping strategy that actually worsened his overall control.

Rather than jumping directly to a new device, the care team first offered the patient structured diabetes education and psychological support to address both his medical needs and his emotional burden. He was then enrolled in a research program and switched to the MiniMed 780G Advanced Hybrid Closed Loop (AHCL) system.

The AHCL system works by continuously reading glucose levels and automatically adjusting insulin delivery throughout the day and night. This automation is designed to reduce the burden of constant insulin dose decisions and to help achieve steadier blood sugar levels, even in people with long-standing, complicated diabetes.

After nine months on the AHCL system, combined with ongoing education and support, the patient showed meaningful improvements in his blood sugar metrics. His average glucose dropped to 128 mg/dL, and he spent 91% of his time within his target glucose range. Importantly, he had no episodes of severe hypoglycemia during the follow-up period—a major shift from his previous fear-driven insulin underdosing.

Beyond the numbers, the patient's psychological well-being improved noticeably. Standardized mental health assessments showed reductions in depressive symptoms, diabetes-related distress, and overall psychological burden. His sense of well-being increased, suggesting that the combination of technology, education, and mental health support addressed both his medical and emotional needs.

This case report demonstrates that even patients with very long-standing diabetes and serious complications can achieve meaningful improvements with the right combination of tools and support. The key takeaway is that advanced insulin technology—while powerful—works best when paired with structured education and psychological care.

The patient's experience shows that age and duration of diabetes are not barriers to benefiting from newer systems. However, this is a single case study, and results may vary from person to person. Anyone considering such a technology should discuss the potential benefits and challenges with their own care team.

Source: Frontiers in clinical diabetes and healthcare. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.